



EuroSIDA Newsletter

September 2016

ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,

We hope all of you had a great summer. We send you many autumn greetings and as always, thank you for your continued excellent work and important contributions to the EuroSIDA study.

We are very excited to be working on redefining the scientific and operational scope of EuroSIDA. As the first stage, we have spent the past months thoroughly restructuring the data collection, as communicated in the July [newsletter](#). We are confident that the revisions will ensure an even higher quality of data accuracy, relevance and reliability, and that the changes will help ensure that EuroSIDA remains in the forefront of contributing with important research about the HIV epidemic across Europe.

As you know, we have reduced the follow-up form substantially in order to reduce your workload and increase data quality. Furthermore, data collection will be reduced to once annually; The next dataset (44) will be released 1st October 2016 and should be completed by 1st December. Hereafter the datasets will be released every June, the next one being dataset 45 in June 2017.

Glasgow 2016

We would like to invite all EuroSIDA investigators to join us at the

**EuroSIDA investigator meeting
at the 2016 HIV Glasgow Drug Therapy Conference
Monday 24 October 12.30-14.00
In the LEVEN room**

We will dedicate the meeting to discussing the future scientific scope of EuroSIDA and once again invite all investigators to participate in the scientific working group. Further, we will briefly introduce the changes to the data collection described in this newsletter.

Please confirm if you are attending, if you have not already done so, to eurosida.rigshospitalet@regionh.dk (lunch will be served)

**EuroSIDA investigator
meeting
at the 2016 HIV Glasgow Drug
Therapy Conference
Monday 24 October 12.30-
14.00
In the LEVEN room**

Dataset 44

The dataset 44 package will be sent to centers **1 October 2016** and the deadline for submission for all sites is **1 December 2016**.

Expect a phone call from the coordinating office!

In order to clarify any question you may have regarding the new data collection structure, we will be contacting all sites by phone during the month of September.

DAD

Please remember that DAD forms should no longer be completed and sent to CHIP. However, **all events are still collected as part of the regular follow-up**.

Reimbursement

The 2016 reimbursement will be made to sites in October 2016, for activities covering the period of dataset 42 (summer 2015) and dataset 43.

In the future data collection, reimbursement will be based on provision of a set of core data that should be available for all patients.

New EuroSIDA Logo

The EuroSIDA logo has endured a



facelift, we hope you like it! Please find it at the top right of the newsletter.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosidea.rigshospitalet@regionh.dk
No question is too small or too big, we are happy to assist in all matters!



Glasgow presentations

We are very happy to announce that the EuroSIDA abstract "*Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe*" has been **accepted as an oral presentation** in Glasgow! The presentation is scheduled to take place on **Monday 24 October**.

Furthermore, EuroSIDA will be represented at Glasgow with an additional **two thistle poster presentations!**:

- **The extent of B-cell activation and dysfunction preceding lymphoma development**, presented by Leah Shepherd
- **Aging and the evolution of comorbidities among HIV patients in the EuroSIDA cohort**, presented by Sara Lopes

Exact time and place for the presentations will be available on the CHIP webpage as soon as they are known.

We look forward to seeing you in Glasgow!

New REDCap forms

In connection with the streamlining of EuroSIDA data collection you will find **two new forms in REDCap**.

The EuroSIDA follow-up in REDCap now consists of the following forms:

- **The EuroSIDA core Follow-up form:** For all patients enrolled into EuroSIDA prior to 15th of September 2016
- **The EuroSIDA HCV Treatment form:** for Cohort 10 patients where HCV treatment was ongoing at enrolment or has started after enrolment, and for all cohort 1-9 patients where HCV treatment was ongoing 1 June 2014 or has commenced after 1 June 2014.
- **The EuroSIDA HCV Treatment Adverse Event form:** For all patients who have stopped HCV treatment earlier than planned due to toxicity/intolerance
- **The EuroSIDA Hypersensitivity reaction/liver toxicity event form:** For all patients that have stopped Integrase inhibitor treatment due to liver toxicity or a hypersensitivity reaction/rash
- **The EuroSIDA Enrolment form:** For new patients to be enrolled into EuroSIDA cohort 10

New forms:

- **The EuroSIDA CoDe form:** The CoDe form is now integrated into REDCap, and should be completed for all patients who dies
- **The EuroSIDA HCV Follow-up form:** All known anti-HCV positive patients will have a pre-loaded form in REDCap, like the core FU form, to be completed in connection with dataset 44. If a patient has been tested anti-HCV positive since last follow-up dataset, you must create a new form/record, like you do with the HCV Treatment and HCV Treatment Adverse Event form.

Electronic reporting

The sites that report follow-up data in a database dump should continue to **deliver data in Access format**. We are currently revising the SOP for electronic data transfer; please adapt your data accordingly in the coming dataset. The sites that deliver only laboratory data in data dump, should also report in Access template and follow the SOP.

Although most follow-up data can be transferred electronically, we still ask the sites that deliver all data in Access to please complete the following forms in REDCap:

- **The EuroSIDA HCV Treatment Adverse Event form**
- **The EuroSIDA Hypersensitivity reaction/liver toxicity event form**
- **The EuroSIDA CoDe form**

Please contact the EuroSIDA coordinating centre if you need a REDCap password.

EuroSIDA cohort 10

Enrolment in cohort 10 has stagnated as we approach 4,000 newly enrolled HIV/HCV coinfecting patients. Thank you profoundly to all enrolling sites for your very important contribution!

Enrolment in cohort 10 still continues for those sites that have not yet met their targets. If you still have HIV-positive patients with positive HCV-antibody status not enrolled in EuroSIDA already, please continue to enroll patients.

PUBLICATIONS

Total number of publications in 2016: 17

Publications since last newsletter April 2016: 6

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons. N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A D'Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group.

Eur J Prev Cardiol. 2016 Jan;23(2):214-23.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease

and diabetes: the D:A:D study. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d'Arminio Monforte; Andrew Phillips; Rainer Weber; Jens Lundgren; Matthew G Law; The D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68.

Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. JV Lazarus, K Laut, K Safreed-Harmon, L Peters, M Johnson, G Fätkenheuer, I Khromova, L Vandekerckhove, K Maciejewska, R Radoi, AL Ridolfo, A Mocroft, on behalf of EuroSIDA in EuroCoord.

BMC Infect Dis. 2016 Jul 20;16:335.

The cardiovascular risk management for people living with HIV in Europe: how well are we doing? M Shahmanesh, A Schultze, F Burns, O Kirk, J Lundgren, C Mussini, C Pedersen, S De Wit, G Kutsyna, A Mocroft on behalf of EuroSIDA in EuroCoord.

AIDS. 2016 Jul 22. [Epub ahead of print]

Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. L Ryom, JD Lundgren, M Ross, O Kirk, M Law, P Morlat, C Smit, E Fontas, CA Fux, CI Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group

J Infect Dis. 2016 Aug 2. pii: jiw342. [Epub ahead of print]

Changing incidence and risk factors for Kaposi sarcoma by time since starting antiretroviral therapy: Collaborative analysis of 21 European cohort studies. The Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.

Clin Infect Dis. 2016 Aug 17. [Epub ahead of print]

All publications may be found [HERE](#)

Thank you for a continuous rewarding and successful collaboration!

EuroSIDA Coordinating Centre. Rigshospitalet, CHIP, Department of Infectious Diseases, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: EuroSIDA.rigshospitalet@regionh.dk

Web: www.regionh.dk www.chip.dk